Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 5 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Corcept Therapeutics Incorporated is currently managing 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 8 distinct examiners and 5 distinct art units. D Margaret M Seaman is the busiest examiner, though she only handles 1 pending office action. This distribution shows a high level of examiner diversity, with each of the 8 pending actions assigned to a different individual.
The 8 pending actions are concentrated within 5 distinct art units, suggesting some technical overlap in the company's filings. Because each examiner is only handling 1 pending matter, the company must manage relationships with 8 different officials simultaneously. This broad distribution across examiners despite a smaller number of art units may reflect a diverse range of pharmaceutical technologies being pursued. The lack of a single examiner handling multiple cases means the company cannot rely on a single point of contact for its pending portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| §112 only | 2 (20%) |
| Double-patenting only | 4 (40%) |
| Double-patenting + other | 2 (20%) |
| Multi-statute (no §101) | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.5% | +8.0% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 75.2% | +34.0% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| KUCHARCZK, JED A | 1 | 80.2% | +16.7% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18676126 | SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | WILLIS, DOUGLAS M | — |
| 18686112 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE AND ITS SYMPTOMS | KUCHARCZK, JED A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18342239 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | LEE, CHIHYI NMN | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18342239 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | LEE, CHIHYI NMN | 55d |
| 18798160 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | WHITE, DAWANNA SHAR-DAY | — |
| 18777823 | Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator | ROZOF, TIMOTHY R | — |
| 18764781 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | HEASLEY, MEGHAN CHRISTINE | — |
| 18676126 | SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | WILLIS, DOUGLAS M | — |
| 18686112 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE AND ITS SYMPTOMS | KUCHARCZK, JED A | — |
| 18584163 | METHODS OF PREPARING INTERMEDIATES OF HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | MCDOWELL, BRIAN E | — |
| 18444342 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1626 | 1 |
| 1623 | 1 |
| 1643 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18908611 | POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | SEAMAN, D MARGARET M | — | DP | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18798160 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | WHITE, DAWANNA SHAR-DAY | — | DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18777823 | Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator | ROZOF, TIMOTHY R | — | DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18764781 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | HEASLEY, MEGHAN CHRISTINE | 1626 | DP | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18676126 | SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | May 28, 2024 |
| 18686112 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE AND ITS SYMPTOMS | KUCHARCZK, JED A | 1623 | §103§112DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18584163 | METHODS OF PREPARING INTERMEDIATES OF HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | MCDOWELL, BRIAN E | 1624 | §112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18444342 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | RODRIGUEZ, RAYNA B | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18460226 | METHODS OF ASSESSING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATION AND OF IDENTIFYING AND TREATING PATIENTS LIKELY TO BENEFIT FROM GLUCOCORTICOID RECEPTOR MODULATION | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18342239 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | LEE, CHIHYI NMN | 1628 | §102§103§112Other | Non-Final OA | 55d | Pending | Jun 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial